FindTrial
Sign In

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00046137
Enrollment
Unknown
Registered
2002-09-23
Start date
Unknown
Completion date
Unknown
Last updated
2006-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis, Postmenopausal

Brief summary

The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether teriparatide and raloxifene together can help patients with osteoporosis more than teriparatide alone.

Interventions

DRUGteriparatide
DRUGraloxifene
DRUGplacebo

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Must be diagnosed with osteoporosis. * Must be female, age 45 through 85. * Must be at least 5 years postmenopausal. * Must be free of other severe or chronically disabling conditions. * Must be able to properly use injection device.

Exclusion criteria

* Must not have bone diseases other than osteoporosis. * Must not have history of certain cancers. * Must not have certain medical diseases (inflammatory bowel disease, malabsorption syndrome, kidney or bladder stones, venous thrombi or emboli, recent vaginal bleeding due to unknown causes). * Must not have taken or are currently taking certain types of medicines. * Must not have known allergy to the study agent or SERM.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026